A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.

IF 2.2 Q2 MEDICINE, GENERAL & INTERNAL
Laura Patton, Valeria Reverdito, Alessandra Bellucci, Micaela Bortolon, Annalisa Macrelli, Lorenzo Ricolfi
{"title":"A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.","authors":"Laura Patton, Valeria Reverdito, Alessandra Bellucci, Micaela Bortolon, Annalisa Macrelli, Lorenzo Ricolfi","doi":"10.3390/clinpract15070128","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Lipedema is a chronic disease of subcutaneous adipose tissue that predominantly affects women and is frequently associated with endocrinopathies such as insulin resistance and obesity. Its pathogenesis is still unclear, and treatment, which requires a multi-disciplinary approach, is prolonged over time and is not always effective. There is currently no drug treatment available for this disease. <b>Methods:</b> Five different cases of women with lipedema and insulin resistance, treated with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and once-weekly exenatide, in association or not with lifestyle changes (diet or physical activity) for 3 to 6 months are described. Changes in anthropometric parameters, symptoms, clinical findings and the thickness of superficial adipose tissue measured by ultrasound were evaluated. <b>Results:</b> Treatment with exenatide, whether combined with a change in diet or physical activity, resulted in a reduction in the characteristic symptoms of lipedema, in pain evoked by pinching the adipose tissue fold and in the thickness of subcutaneous adipose tissue at the levels of the lower limbs, abdomen and upper limbs. In four out of five cases, a reduction in body weight was observed, particularly during the first three months of treatment and in cases with greater metabolic impairment. Clinical, instrumental and subjective improvements were also observed in cases where there was no reduction in body weight and in patients who had previously undergone lower limb liposuction. <b>Conclusions:</b> The improvement in symptoms and clinical signs of lipedema, in addition to the reduction in adipose tissue in patients with lipedema and insulin resistance with exenatide, suggests a novel pharmacological approach to the disease, which can be combined with other conservative and surgical treatments to promote weight reduction. These results also highlight the association of this disease with metabolic alterations and the fundamental role of an accurate diagnosis followed by the treatment of comorbidities and excess weight in these patients.</p>","PeriodicalId":45306,"journal":{"name":"Clinics and Practice","volume":"15 7","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293800/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/clinpract15070128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lipedema is a chronic disease of subcutaneous adipose tissue that predominantly affects women and is frequently associated with endocrinopathies such as insulin resistance and obesity. Its pathogenesis is still unclear, and treatment, which requires a multi-disciplinary approach, is prolonged over time and is not always effective. There is currently no drug treatment available for this disease. Methods: Five different cases of women with lipedema and insulin resistance, treated with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and once-weekly exenatide, in association or not with lifestyle changes (diet or physical activity) for 3 to 6 months are described. Changes in anthropometric parameters, symptoms, clinical findings and the thickness of superficial adipose tissue measured by ultrasound were evaluated. Results: Treatment with exenatide, whether combined with a change in diet or physical activity, resulted in a reduction in the characteristic symptoms of lipedema, in pain evoked by pinching the adipose tissue fold and in the thickness of subcutaneous adipose tissue at the levels of the lower limbs, abdomen and upper limbs. In four out of five cases, a reduction in body weight was observed, particularly during the first three months of treatment and in cases with greater metabolic impairment. Clinical, instrumental and subjective improvements were also observed in cases where there was no reduction in body weight and in patients who had previously undergone lower limb liposuction. Conclusions: The improvement in symptoms and clinical signs of lipedema, in addition to the reduction in adipose tissue in patients with lipedema and insulin resistance with exenatide, suggests a novel pharmacological approach to the disease, which can be combined with other conservative and surgical treatments to promote weight reduction. These results also highlight the association of this disease with metabolic alterations and the fundamental role of an accurate diagnosis followed by the treatment of comorbidities and excess weight in these patients.

关于脂水肿药物治疗的疗效的一系列案例:意大利使用艾塞那肽的经验。
背景:脂肪水肿是一种主要影响女性的皮下脂肪组织慢性疾病,通常与胰岛素抵抗和肥胖等内分泌疾病有关。其发病机制尚不清楚,需要多学科联合治疗,治疗时间较长,并不总是有效。目前还没有治疗这种疾病的药物。方法:5例不同的脂水肿和胰岛素抵抗的妇女,用胰高血糖素样肽-1受体激动剂(GLP-1 RAs)和每周一次的艾塞那肽治疗,与生活方式改变(饮食或体育活动)相关或不相关3 - 6个月。评估超声测量的人体测量参数、症状、临床表现和浅表脂肪组织厚度的变化。结果:用艾塞那肽治疗,无论是结合饮食或体力活动的改变,导致脂肪水肿的特征性症状减轻,由脂肪组织褶皱引起的疼痛减轻,下肢、腹部和上肢的皮下脂肪组织厚度减轻。在五分之四的病例中,观察到体重减轻,特别是在治疗的前三个月和代谢障碍较大的病例中。在体重没有减轻的病例和以前接受过下肢吸脂术的患者中,也观察到临床、仪器和主观方面的改善。结论:艾塞那肽在改善脂肪水肿和胰岛素抵抗患者的症状和临床体征的同时,还能减少脂肪组织,提示了一种新的药物治疗方法,可与其他保守治疗和手术治疗相结合,促进体重减轻。这些结果还强调了这种疾病与代谢改变的关联,以及准确诊断并治疗这些患者的合并症和超重的基本作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinics and Practice
Clinics and Practice MEDICINE, GENERAL & INTERNAL-
CiteScore
2.60
自引率
4.30%
发文量
91
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信